



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/483678/2013

European Medicines Agency decision

P/0199/2013

of 2 September 2013

on the acceptance of a modification of an agreed paediatric investigation plan for L-Cysteinyl-L-prolyl-L-alanyl-L-valyl-L-lysyl-L-arginyl-L-aspartyl-L-valyl-L-aspartyl-L-leucyl-L-phenylalanyl-L-leucyl-L-threonine, hydrochloride salt / L-Glutamyl-L-glutaminyl-L-valyl-L-alanyl-L-glutaminyl-L-tyrosyl-L-lysyl-L-alanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-leucyl-L-glutamyl-L-asparaginyll-L-alanine, acetate salt / L-Lysyl-L-alanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-leucyl-L-glutamyl-L-asparaginyll-L-alanyl-L-arginyl-L-iso-leucyl-L-leucyl-L-lysyl-L-asparaginyll-L-cysteinyl-L-valine, acetate salt / L-Arginyl-L-iso-leucyl-L-leucyl-L-lysyl-L-asparaginyll-L-cysteinyl-L-valyl-L-aspartyl-L-alanyl-L-lysyl-L-methionyl-L-threonyl-L-glutamyl-L-glutamyl-L-aspartyl-L-lysyl-L-glutamic acid, acetate salt / L-Lysyl-L-glutamyl-L-asparaginyll-L-alanyl-L-leucyl-L-seryl-L-leucyl-L-leucyl-L-aspartyl-L-lysyl-L-iso-leucyl-L-tyrosyl-L-threonyl-L-seryl-L-prolyl-L-leucine, acetate salt / L-Threonyl-L-alanyl-L-methionyl-L-lysyl-L-lysyl-L-iso-leucyl-L-glutaminyl-L-aspartyl-L-cysteinyl-L-tyrosyl-L-valyl-L-glutamyl-L-asparaginyll-glycyl-L-leucyl-L-iso-leucine, acetate salt / L-Seryl-L-arginyl-L-valyl-L-leucyl-L-aspartyl-glycyl-L-leucyl-L-valyl-L-methionyl-L-threonyl-L-threonyl-L-iso-leucyl-L-seryl-L-seryl-L-seryl-L-lysine, acetate salt, (EMA-001054-PIP01-10-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0199/2013

of 2 September 2013

on the acceptance of a modification of an agreed paediatric investigation plan for L-Cysteinyl-L-prolyl-L-alanyl-L-valyl-L-lysyl-L-arginyl-L-aspartyl-L-valyl-L-aspartyl-L-leucyl-L-phenylalanyl-L-leucyl-L-threonine, hydrochloride salt / L-Glutamyl-L-glutaminyl-L-valyl-L-alanyl-L-glutaminyl-L-tyrosyl-L-lysyl-L-alanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-leucyl-L-glutamyl-L-asparaginyl-L-alanine, acetate salt / L-Lysyl-L-alanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-leucyl-L-glutamyl-L-asparaginyl-L-alanyl-L-arginyl-L-iso-leucyl-L-leucyl-L-lysyl-L-asparaginyl-L-cysteinyl-L-valine, acetate salt / L-Arginyl-L-iso-leucyl-L-leucyl-L-lysyl-L-asparaginyl-L-cysteinyl-L-valyl-L-aspartyl-L-alanyl-L-lysyl-L-methionyl-L-threonyl-L-glutamyl-L-glutamyl-L-aspartyl-L-lysyl-L-glutamic acid, acetate salt / L-Lysyl-L-glutamyl-L-asparaginyl-L-alanyl-L-leucyl-L-seryl-L-leucyl-L-leucyl-L-aspartyl-L-lysyl-L-iso-leucyl-L-tyrosyl-L-threonyl-L-seryl-L-prolyl-L-leucine, acetate salt / L-Threonyl-L-alanyl-L-methionyl-L-lysyl-L-lysyl-L-iso-leucyl-L-glutaminyl-L-aspartyl-L-cysteinyl-L-tyrosyl-L-valyl-L-glutamyl-L-asparaginyl-glycyl-L-leucyl-L-iso-leucine, acetate salt / L-Seryl-L-arginyl-L-valyl-L-leucyl-L-aspartyl-glycyl-L-leucyl-L-valyl-L-methionyl-L-threonyl-L-threonyl-L-iso-leucyl-L-seryl-L-seryl-L-seryl-L-lysine, acetate salt, (EMA-001054-PIP01-10-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/244/2011 issued on 7 October 2011, and the decision P/0085/2012 issued on 21 May 2012,

Having regard to the application submitted by Circassia Limited on 29 April 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 July 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for L-Cysteinyl-L-prolyl-L-alanyl-L-valyl-L-lysyl-L-arginyl-L-aspartyl-L-valyl-L-aspartyl-L-leucyl-L-phenylalanyl-L-leucyl-L-threonine, hydrochloride salt / L-Glutamyl-L-glutaminyl-L-valyl-L-alanyl-L-glutaminyl-L-tyrosyl-L-lysyl-L-alanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-leucyl-L-glutamyl-L-asparaginyl-L-alanine, acetate salt / L-Lysyl-L-alanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-leucyl-L-glutamyl-L-asparaginyl-L-alanyl-L-arginyl-L-isoleucyl-L-leucyl-L-lysyl-L-asparaginyl-L-cysteinyl-L-valine, acetate salt / L-Arginyl-L-isoleucyl-L-leucyl-L-lysyl-L-asparaginyl-L-cysteinyl-L-valyl-L-aspartyl-L-alanyl-L-lysyl-L-methionyl-L-threonyl-L-glutamyl-L-glutamyl-L-aspartyl-L-lysyl-L-glutamic acid, acetate salt / L-Lysyl-L-glutamyl-L-asparaginyl-L-alanyl-L-leucyl-L-seryl-L-leucyl-L-leucyl-L-aspartyl-L-lysyl-L-isoleucyl-L-tyrosyl-L-threonyl-L-seryl-L-prolyl-L-leucine, acetate salt / L-Threonyl-L-alanyl-L-methionyl-L-lysyl-L-lysyl-L-isoleucyl-L-glutaminyl-L-aspartyl-L-cysteinyl-L-tyrosyl-L-valyl-L-glutamyl-L-asparaginyl-glycyl-L-leucyl-L-isoleucine, acetate salt / L-Seryl-L-arginyl-L-valyl-L-leucyl-L-aspartyl-glycyl-L-leucyl-L-valyl-L-methionyl-L-threonyl-L-threonyl-L-isoleucyl-L-seryl-L-seryl-L-seryl-L-lysine, acetate salt, powder for solution for injection, intradermal use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Circassia Limited, Magdalen Centre, Robert Robinson Avenue, The Oxford Science Park, OX4 4GA – Oxford, United Kingdom.

Done at London, 2 September 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/273229/2013

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001054-PIP01-10-M02

Scope of the application

Active substance(s):

L-Cysteiny-L-prolyl-L-alanyl-L-valyl-L-lysyl-L-arginyl-L-aspartyl-L-valyl-L-aspartyl-L-leucyl-L-phenylalanyl-L-leucyl-L-threonine, hydrochloride salt / L-Glutamyl-L-glutaminyl-L-valyl-L-alanyl-L-glutaminyl-L-tyrosyl-L-lysyl-L-alanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-leucyl-L-glutamyl-L-asparaginy-L-alanine, acetate salt / L-Lysyl-L-alanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-leucyl-L-glutamyl-L-asparaginy-L-alanyl-L-arginyl-L-isoleucyl-L-leucyl-L-lysyl-L-asparaginy-L-cysteiny-L-valine, acetate salt / L-Arginy-L-isoleucyl-L-leucyl-L-lysyl-L-asparaginy-L-cysteiny-L-valyl-L-aspartyl-L-alanyl-L-lysyl-L-methionyl-L-threony-L-glutamyl-L-glutamyl-L-aspartyl-L-lysyl-L-glutamic acid, acetate salt / L-Lysyl-L-glutamyl-L-asparaginy-L-alanyl-L-leucyl-L-seryl-L-leucyl-L-leucyl-L-aspartyl-L-lysyl-L-isoleucyl-L-tyrosyl-L-threony-L-seryl-L-prolyl-L-leucine, acetate salt / L-Threony-L-alanyl-L-methionyl-L-lysyl-L-lysyl-L-isoleucyl-L-glutaminyl-L-aspartyl-L-cysteiny-L-tyrosyl-L-valyl-L-glutamyl-L-asparaginy-glycyl-L-leucyl-L-isoleucine, acetate salt / L-Seryl-L-arginyl-L-valyl-L-leucyl-L-aspartyl-glycyl-L-leucyl-L-valyl-L-methionyl-L-threony-L-threony-L-isoleucyl-L-seryl-L-seryl-L-seryl-L-lysine, acetate salt

Condition(s):

Treatment of perennial allergic rhinitis

Pharmaceutical form(s):

Powder for solution for injection

Route(s) of administration:

Intradermal use

Name / corporate name of the PIP applicant:

Circassia Limited



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Circassia Limited submitted to the European Medicines Agency on 29 April 2013 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/244/2011 issued on 7 October 2011, and the decision P/0085/2012 issued on 21 May 2012.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 22 May 2013.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 19 July 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: treatment of perennial allergic rhinitis

The waiver applies to:

- All subsets of the paediatric population from birth to less than 5 years of age;
- for powder for solution for injection, intradermal use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan

2.1. Condition: treatment of perennial allergic rhinitis

2.1.1. Indication targeted by the PIP

Treatment of cat allergen induced rhino-conjunctivitis in patients with clinically relevant symptoms.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 5 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality	0	Not applicable
Non-clinical	1	Measure 1 Juvenile toxicity study
Clinical	3	Measure 2 Double-blind, randomised, multi-centre, superiority, multiple-dose, placebo-controlled, parallel group study to evaluate efficacy and safety of Cat-PAD in cat allergic adolescents (and in adults). Measure 3 Open label study with placebo run-in period to assess safety and tolerability of intradermal Cat-PAD administration via MicronJet 600 in cat allergic children from 5 to less than 12 years. Measure 4 Double-blind, randomised, multi-centre, superiority, multiple-dose, placebo-

		controlled, parallel group study to evaluate efficacy and safety of Cat-PAD in cat allergic children from 5 to less than 12 years.
--	--	--

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By April 2018
Deferral for one or more studies contained in the paediatric investigation plan:	Yes